Chardan Capital Has Lowered Expectations for Prothena (NASDAQ:PRTA) Stock Price
Prothena (NASDAQ:PRTA – Free Report) had its price objective lowered by Chardan Capital from $40.00 to $18.00 in a research note released on Tuesday morning,Benzinga reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock. A number of other equities research analysts have also recently commented on the stock. Oppenheimer raised their […]
Prothena (NASDAQ:PRTA – Free Report) had its price objective lowered by Chardan Capital from $40.00 to $18.00 in a research note released on Tuesday morning,Benzinga reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock. A number of other equities research analysts have also recently commented on the stock. Oppenheimer raised their […]
